Search
The National Medical Products Administration of China has granted approval to Tirzepatide Injection, marking it as the pioneering and sole prescription medication for adults suffering from moderate to severe obstructive sleep apnea (OSA) alongside obesity. When combined with dietary management and increased physical activity, this drug effectively addresses patients' sleep disorders. Clinical trials have revealed Tirzepatide's capability to substantially decrease the frequency of apnea-hypopnea events, enhance the symptom relief rate, and facilitate long-term weight loss. It has demonstrated excellent safety and tolerability profiles, with most common adverse reactions being mild to moderate gastrointestinal discomforts. This approval introduces a novel therapeutic avenue for patients with moderate to severe OSA complicated by obesity.
-
C114 Communication Network -
Communication Home
